Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Links shared publicly online about this topic.

956
total visits

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation o

View full resource at news-medical.net

Tags: Pain Medication, Depression, Antidepressant, Major Depression, Disease and Condition, Pregnancy, Desyrel, News

Most Recently Shared on August 11, 2010 at 10:45 am By:

News-Medical.Net

Pregnancy News: Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.: Labopharm Inc. to... http://bit.ly/9JufSO

2 years ago...

Retweet

Favorite

Angelini Labopharm Announces The U.S. Launch Of OLEPTRO™ For The Treatment Of Major Depressive Disorder In Adults

medicalnewstoday.com — “Angelini Labopharm announced that OLEPTRO™ (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, is now commercially available i” View full resource at medicalnewstoday.com